Theriva Biologics, Inc. (TOVX)
| Market Cap | 10.78M +183.6% |
| Revenue (ttm) | 300,000 |
| Net Income | -13.13M |
| EPS | -0.42 |
| Shares Out | 45.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 207,080 |
| Open | 0.2341 |
| Previous Close | 0.2308 |
| Day's Range | 0.2310 - 0.2389 |
| 52-Week Range | 0.1628 - 0.8632 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | 2.50 (+964.74%) |
| Earnings Date | Aug 11, 2026 |
About TOVX
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral c... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for TOVX stock is "Buy." The 12-month stock price target is $2.5, which is an increase of 964.74% from the latest price.
News
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
– First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metas...
Theriva Biologics Earnings release: Q2 2026
Theriva Biologics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Theriva Biologics Quarterly report: Q2 2026
Theriva Biologics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in metastatic pancreatic ductal adenocarcinoma (PDAC) -
Theriva Biologics gets regulatory authorization to proceed with VIRAGE2 in Spain
Theriva Biologics (TOVX) announced that the Spanish Agency of Medicines and Medical Devices, or AEMPS, has authorized the company to initiate the VIRAGE2 clinical trial, entitled “A Phase IIa, single-...
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial - - Study builds on positive clinical data from the recent VIR...
Theriva Biologics Proxy statement: Proxy filing
Theriva Biologics filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics Proxy statement: Proxy filing
Theriva Biologics filed a proxy statement on June 18, 2026, providing details for shareholder voting and corporate governance matters.
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor du...
Theriva Biologics Slides: Corporate presentation
Theriva Biologics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
– Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) –
Theriva Biologics Earnings release: Q1 2026
Theriva Biologics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Theriva Biologics Quarterly report: Q1 2026
Theriva Biologics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Theriva Biologics Proxy statement: Proxy filing
Theriva Biologics filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics Proxy statement: Proxy filing
Theriva Biologics filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics to present additional data on Phase 2b VCN-01Clinical Trial
Theriva Biologics (TOVX) “announced an upcoming poster presentation of new data and subgroup analyses from the VIRAGE Phase 2b clinical trial evaluating VCN-01 (zabilugene almadenorepvec) plus gemcita...
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
- Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients a...
Theriva Biologics upgraded to Buy at Maxim on clearer VCN-01 path
As previously reported, Maxim Jason McCarthy upgraded Theriva Biologics (TOVX) to Buy from Hold with a $1 price target The firm says the the path forward for VCN-01 in first-line…
Theriva Biologics upgraded to Buy from Hold at Maxim
Maxim upgraded Theriva Biologics (TOVX) to Buy from Hold with a $1 price target
Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA
Theriva Biologics (TOVX) announced the outcomes of a recent Type B End-of-Phase 2 meeting with the FDA regarding the design of a Phase 3 clinical study of lead clinical candidate…
Theriva Biologics Proxy statement: Proxy Filing
Theriva Biologics filed a proxy statement on March 16, 2026, providing details for shareholder voting and corporate governance matters.
Theriva Biologics price target lowered to $4 from $7 at Alliance Global
Alliance Global lowered the firm’s price target on Theriva Biologics (TOVX) to $4 from $7 and keeps a Buy rating on the shares following the Q4 report. The firm cites…
Theriva Biologics reports FY25 EPS ($2.08) vs. ($19.03) last year
“We are very pleased to have completed the licensing of our versatile Phase 2-ready asset SYN-020 to Rasayana Therapeutics, executing on our plan to derive value from our GI portfolio…
Theriva Biologics sees cash runway into 1Q27
Cash and cash equivalents totaled $13.1 million as of December 31, 2025, compared to $11.6 million as of December 31, 2024. The Company’s current cash of approximately $15.2 million at…
Theriva Biologics Earnings release: Q4 2025
Theriva Biologics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.